Qu'est-ce qu'une échelle d'évaluation psychiatrique ?

C'est un outil pour quantifier les symptômes et évaluer l'état mental.

Comment sont-elles utilisées dans le diagnostic ?

Elles aident à établir un diagnostic précis en mesurant les symptômes.

Quels types de troubles peuvent être évalués ?

Elles peuvent évaluer des troubles comme la dépression, l'anxiété, et la schizophrénie.

Qui peut administrer ces échelles ?

Elles peuvent être administrées par des professionnels de santé qualifiés.

Sont-elles standardisées ?

Oui, elles sont souvent standardisées pour assurer la fiabilité des résultats.

Quels symptômes mesurent-elles ?

Elles mesurent des symptômes comme l'humeur, l'anxiété, et les comportements.

Peuvent-elles évaluer la sévérité des symptômes ?

Oui, elles évaluent la sévérité des symptômes pour guider le traitement.

Comment les symptômes sont-ils notés ?

Les symptômes sont notés sur une échelle numérique ou descriptive.

Y a-t-il des échelles pour les enfants ?

Oui, certaines échelles sont spécifiquement conçues pour les enfants et adolescents.

Les symptômes peuvent-ils fluctuer ?

Oui, les symptômes peuvent varier selon les circonstances et le temps.

Peuvent-elles aider à la prévention des troubles ?

Elles peuvent identifier des symptômes précoces et aider à la prévention.

Comment sont-elles utilisées en prévention ?

Elles sont utilisées pour détecter des signes précoces et orienter les interventions.

Y a-t-il des échelles spécifiques pour la prévention ?

Certaines échelles sont spécifiquement conçues pour évaluer le risque de troubles.

Peuvent-elles évaluer le stress ?

Oui, certaines échelles mesurent le stress, un facteur de risque pour les troubles.

Sont-elles utiles pour les populations à risque ?

Oui, elles sont particulièrement utiles pour les populations à risque élevé.

Comment les échelles influencent-elles le traitement ?

Elles aident à adapter le traitement en fonction de l'évolution des symptômes.

Peuvent-elles prédire la réponse au traitement ?

Certaines échelles peuvent aider à prédire la réponse au traitement en cours.

Sont-elles utilisées pour suivre l'évolution ?

Oui, elles sont souvent utilisées pour suivre l'évolution des symptômes au fil du temps.

Peuvent-elles évaluer l'efficacité d'un traitement ?

Oui, elles permettent d'évaluer l'efficacité des interventions thérapeutiques.

Les échelles sont-elles adaptées à tous les traitements ?

Elles peuvent être adaptées à divers traitements, mais pas tous les types.

Quelles complications peuvent survenir sans évaluation ?

Sans évaluation, des complications comme l'aggravation des symptômes peuvent survenir.

Les échelles aident-elles à prévenir les complications ?

Oui, elles permettent d'identifier les problèmes avant qu'ils ne s'aggravent.

Peuvent-elles identifier des comorbidités ?

Certaines échelles peuvent aider à identifier des comorbidités psychiatriques.

Comment les complications sont-elles évaluées ?

Elles sont évaluées par des scores et des descriptions des symptômes associés.

Les complications affectent-elles le traitement ?

Oui, les complications peuvent nécessiter des ajustements dans le traitement.

Quels facteurs de risque sont évalués ?

Les facteurs de risque incluent l'hérédité, le stress et les antécédents médicaux.

Les échelles mesurent-elles l'impact des facteurs environnementaux ?

Oui, elles peuvent évaluer l'impact des facteurs environnementaux sur la santé mentale.

Peuvent-elles identifier des comportements à risque ?

Certaines échelles peuvent identifier des comportements à risque liés à la santé mentale.

Comment les facteurs de risque influencent-ils le traitement ?

Ils peuvent influencer le choix du traitement et la stratégie d'intervention.

Les facteurs de risque sont-ils modifiables ?

Certains facteurs de risque, comme le stress, peuvent être modifiés par des interventions.

Échelles d'évaluation en psychiatrie - Informations médicales vérifiées

Smoking cessation and vaccination.

31 Mar 2023

DOI: 10.1183/16000617.0187-2022 PMID: 36948500

A significant proportion of COPD patients (∼40%) continue smoking despite knowing that they have the disease. Smokers with COPD exhibit higher levels of nicotine dependence, and have lower self-effica...

Humans Smoking Cessation Nicotinic Agonists Electronic Nicotine Delivery Systems Tobacco Use Cessation Devices +4 autres

Antidepressants for smoking cessation.

24 05 2023

DOI: 10.1002/14651858.CD000031.pub6 PMID: 37230961

The pharmacological profiles and mechanisms of antidepressants are varied. However, there are common reasons why they might help people to stop smoking tobacco: nicotine withdrawal can produce short-t... To assess the evidence for the efficacy, harms, and tolerability of medications with antidepressant properties in assisting long-term tobacco smoking cessation in people who smoke cigarettes.... We searched the Cochrane Tobacco Addiction Group Specialised Register, most recently on 29 April 2022.... We included randomised controlled trials (RCTs) in people who smoked, comparing antidepressant medications with placebo or no pharmacological treatment, an alternative pharmacotherapy, or the same med... We extracted data and assessed risk of bias using standard Cochrane methods. Our primary outcome measure was smoking cessation after at least six months' follow-up. We used the most rigorous definitio... We included a total of 124 studies (48,832 participants) in this review, with 10 new studies added to this update version. Most studies recruited adults from the community or from smoking cessation cl... There is high-certainty evidence that bupropion can aid long-term smoking cessation. However, bupropion may increase SAEs (moderate-certainty evidence when compared to placebo/no pharmacological treat...

Adolescent Adult Child Humans Young Adult +6 autres

Spirometry as a motivator for smoking cessation among patients attending the smoking cessation clinic of Monastir.

10 06 2022

DOI: 10.1186/s12889-022-13583-1 PMID: 35689178

The choice of spirometry, a biomarker of lung health, as a motivator for smoking cessation is based on its fidelity in emphasizing tobacco adverse effects. Yet, there is a paucity of evidence on its e... We conducted a randomized controlled trial among patients who attended the smoking cessation clinic (SCC) at Fattouma Bourguiba University Hospital in Monastir, from June 2017 to February 2020. Partic... At one-year endpoint, a total of 456 were reachable for assessment, 236 in control group and 220 in spirometry group, which leads to a loss rate equal to 8.8%. One-year smoking cessation rate was high... Smoking cessation is still a challenging procedure with a high risk of relapse, making very valuable any approach that may increase motivation in both unmotivated and motivated smokers. This study is ... Pan African Clinical Trial Registry database ( PACTR202110595729653 ), 06/10/ 2021....

Humans Lung Motivation Smoking Cessation Spirometry

[Smoking Cessation in Patients with COPD].

Apr 2023

DOI: 10.1055/a-2020-4284 PMID: 36958341

Tobacco dependence is a common comorbidity in patients with COPD (Chronic Obstructive Pulmonary Disease) that negatively affects the course of the disease. However, clinically relevant improvement in ...

Humans Smoking Cessation Electronic Nicotine Delivery Systems Smoking Tobacco Use Disorder +1 autres

Interventions for waterpipe smoking cessation.

07 06 2023

DOI: 10.1002/14651858.CD005549.pub4 PMID: 37286509

While cigarette smoking has declined globally, waterpipe smoking is rising, especially among youth. The impact of this rise is amplified by mounting evidence of its addictive and harmful nature. Water... We searched the Cochrane Tobacco Addiction Review Group Specialized Register from database inception to 29 July 2022, using variant terms and spellings ('waterpipe' or 'narghile' or 'arghile' or 'shis... We sought randomized controlled trials (RCTs), quasi-RCTs, or cluster-RCTs of any smoking cessation interventions for people who use waterpipes, of any age or gender. In order to be included, studies ... We used standard Cochrane methods. Our primary outcome was abstinence from waterpipe use at least three months after baseline. We also collected data on adverse events. Individual study effects and po... This review included nine studies, involving 2841 participants. All studies were conducted in adults, and were carried out in Iran, Vietnam, Syria, Lebanon, Egypt, Pakistan, and the USA. Studies were ...

Adolescent Female Humans Bupropion Randomized Controlled Trials as Topic +4 autres

Pulmonary prehabilitation and smoking cessation.

01 Feb 2023

DOI: 10.1097/ACO.0000000000001219 PMID: 36550610

This review aims to summarize the current literature on pulmonary prehabilitation programs, their effects on postoperative pulmonary complications, and the financial implications of implementing these... Prehabilitation is a series of personalized multimodal interventions tailored to individual needs, including lifestyle and behavioral measures. Pulmonary prehabilitation has shown to reduce postoperat... The implications of clinical practice and research findings regarding PPCs are an increased burden of postoperative complications and financial cost to both patients and hospital systems. There is con...

Humans Preoperative Care Preoperative Exercise Smoking Cessation Postoperative Complications +1 autres

Electronic cigarettes for smoking cessation.

17 Nov 2022

DOI: 10.1002/14651858.CD010216.pub7 PMID: 36384212

Electronic cigarettes (ECs) are handheld electronic vaping devices which produce an aerosol by heating an e-liquid. Some people who smoke use ECs to stop or reduce smoking, although some organizations... To examine the effectiveness, tolerability, and safety of using electronic cigarettes (ECs) to help people who smoke tobacco achieve long-term smoking abstinence.... We searched the Cochrane Tobacco Addiction Group's Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO to 1 July 2022, and reference-check... We followed standard Cochrane methods for screening and data extraction. Our primary outcome measures were abstinence from smoking after at least six months follow-up, adverse events (AEs), and seriou... We included 78 completed studies, representing 22,052 participants, of which 40 were RCTs. Seventeen of the 78 included studies were new to this review update. Of the included studies, we rated ten (a... There is high-certainty evidence that ECs with nicotine increase quit rates compared to NRT and moderate-certainty evidence that they increase quit rates compared to ECs without nicotine. Evidence com...

Humans Smoking Cessation Electronic Nicotine Delivery Systems Tobacco Use Cessation Devices Nicotinic Agonists +3 autres

Behavioral activation for smoking cessation and the prevention of smoking cessation-related weight gain: A randomized trial.

01 03 2023

DOI: 10.1016/j.drugalcdep.2023.109792 PMID: 36739753

Post-cessation weight gain (PCWG) is an obstacle to smoking cessation. This trial evaluated a behavioral intervention targeting alternative rewards to smoking and high calorie snacking to promote smok... Adult smokers (n = 288; 119 females, 169 males) received eight weeks of transdermal nicotine and were randomized to eight sessions of behavioral activation for smoking cessation and the mitigation of ... BAS+ and SC did not differ in smoking abstinence rates at the 26-week follow-up (OR=0.80, 95%CI 0.50-1.27, p = 0.34; 18% versus 23%). There were no significant differences in PCWG between BAS+ and SC ... The results do not support the efficacy of BAS+ for smoking cessation and the prevention of PCWG. These findings join a growing body of research highlighting the challenge of minimizing PCWG and promo...

Male Adult Female Humans Smoking Cessation +6 autres

Perceived Stress and Smoking Cessation: The Role of Smoking Urges.

10 01 2023

DOI: 10.3390/ijerph20021257 PMID: 36674019

Despite the fact that perceived stress is related to abstinence smoking outcomes, no studies have investigated the mediational effect of specific tobacco-related variables on this relationship. This s...

Female Humans Male Smoking Cessation Smoking +3 autres

Co-Designing a Smoking Cessation Chatbot: Focus Group Study of End Users and Smoking Cessation Professionals.

19 Aug 2024

DOI: 10.2196/56505 PMID: 39159451

Our prototype smoking cessation chatbot, Quin, provides evidence-based, personalized support delivered via a smartphone app to help people quit smoking. We developed Quin using a multiphase program of... This study aimed to gather and compare feedback on the user experience of the Quin prototype from end users and smoking cessation professionals (SCPs) via a beta testing process to inform ongoing chat... Following active and passive recruitment, we conducted web-based focus groups with SCPs and end users from Queensland, Australia. Participants tested the app for 1-2 weeks prior to focus group discuss... In total, 6 focus groups were completed between August 2022 and June 2023; 3 for SCPs (n=9 participants) and 3 for end users (n=7 participants). Four SCPs had previously smoked, and most end users cur... Feedback from end users and SCPs highlighted the importance of chatbot functionality, as this underpinned Quin's conversation design and relationality. The ready accessibility of accurate cessation in...

Humans Smoking Cessation Focus Groups Queensland Male +4 autres

Échelles d'évaluation en psychiatrie : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Échelle abrégée d'appréciation psychiatrique

Questionnaire sur l'état mental de Kahn

Auteurs principaux

Sources (6285 au total)